ZINZINO AB (PUBL): PRELIMINARY SALES REPORT OCTOBER 2021
Zinzino group revenue decreased with a total of 3%, compared with the previous year.
The revenue in October for Zinzino's sales markets stayed on the same level as last year and amounted to SEK 101.2 (100.8) million. Faun Pharma's external sales decreased by 46% and amounted to SEK 3.7 (6.9) million. Overall, the Group decreased revenues by 3% to SEK 104.9 (107.7) million compared with the previous year.
Accumulated revenue for January – October 2021 increased by 19% to SEK 1074.3 (905.9) million.
Revenues were distributed as follows:
|Regions,MSEK||21-okt||20-okt||Change||YTD 2021||YTD 2020||Change|
|South & West Europe||12.0||9.8||22%||114.8||67.0||71%|
Countries in regions:
-The Nordics: Denmark, Faroe Island, Finland, Iceland, Norway, Sweden
-Central Europe: Austria, Germany, Switzerland
-East Europe: Czech Republic, Slovakia, Hungary, Poland, Romania
-South & West Europe: Cyprus, France, Greece, Italy, Netherlands, Spain, United Kingdom
-The Baltics: Estonia, Latvia, Lithuania
-North America: Canada, USA
-Asia-Pacific: Australia, Hong Kong, India, Malaysia, Singapore, Taiwan, Thailand
For more information:
Dag Bergheim Pettersen CEO Zinzino +47 (0) 932 25 700, zinzino.com
Pictures for publication free of charge:
Marcus Tollbom +46 (0) 70 190 03 12, email@example.com
Certified Adviser: Erik Penser Bank Aktiebolag, +46 (0) 8 463 83 00, email: firstname.lastname@example.org
Zinzino AB (publ) is obliged to publish this information in compliance with current EU regulations governing market abuse. The information was provided by the above contact person for publication at 16:00 the 3rd of November 2021.
Zinzino is a global D2C company from Scandinavia specializing in biomarker-based, personalized nutrition. It is a public limited company with its shares listed on Nasdaq First North Premier Growth Market. Their test-based, scientifically proven nutritional supplements are available in close to 100 markets across the world.
Zinzino owns the Norwegian research and production units BioActive Foods AS and Faun Pharma AS. The company headquarters is in Gothenburg, Sweden with additional offices in Finland, Latvia, Norway, USA, Australia, Hong Kong, Malaysia, India and Taiwan.